Overview

Study of Safety, Tolerability, and Biological Activity of LAM-002A in C9ORF72-Associated Amyotrophic Lateral Sclerosis

Status:
Not yet recruiting

Trial end date:
2022-09-16

Target enrollment:

Participant gender:

Summary

This is a clinical trial to evaluate the safety, tolerability, and biological effect of LAM-002A in adults with C9ORF72-associated ALS (C9ALS).

Phase:

Phase 2

Details

Lead Sponsor:

AI Therapeutics, Inc.